Literature DB >> 17089132

Relation of hippocampal phospho-SAPK/JNK granules in Alzheimer's disease and tauopathies to granulovacuolar degeneration bodies.

Sarita Lagalwar1, Robert W Berry, Lester I Binder.   

Abstract

Protein misfolding is a distinguishing feature of a number of neurodegenerative diseases. Accumulation of misfolded protein often results in cellular lesions, the location of lesions correlating with the nature of symptoms. Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD) and Pick's Disease (PiD) all present with pathological lesions containing hyperphosphorylated filamentous tau protein; however, the location and type of lesion varies. In addition, granulovacuolar degeneration (GVD) bodies have been reported within hippocampal pyramidal neurons in AD, PSP, CBD and PiD tissue. GVDs are defined as electron-dense granules within double membrane-bound cytoplasmic vacuoles. We have previously reported that the phosphorylated form of stress-activated protein kinase/c-Jun N-terminal kinase (p-SAPK/JNK) accumulates in granules within hippocampal pyramidal cell bodies in AD tissue at the time that hyperphosphorylated tau begins to aggregate into early-stage NFTs. We now report that p-SAPK/JNK granules are found within the hippocampal CA1 region of PSP, CBD and PiD cases as well and that these granules are likely GVD bodies. Quantitatively, p-SAPK/JNK granules and GVDs are found in comparable numbers of CA1 cells. Within cells, p-SAPK/JNK granules are distributed throughout the cytoplasm in a manner similar to the distribution of GVDs and a subset of granules co-localize with GVD markers. Ultrastructurally, p-SAPK/JNK granules are located in large cytoplasmic vacuoles, thereby fitting the definition of a GVD body. With the implication of granular p-SAPK/JNK as a marker of GVDs, our study strongly suggests that a heterogeneous group of proteins form GVDs. The mechanism of GVD formation is therefore an interesting one, and is likely separate and distinct from the mechanism of tau inclusion formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089132     DOI: 10.1007/s00401-006-0159-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  19 in total

Review 1.  Tau in Alzheimer disease and related tauopathies.

Authors:  K Iqbal; F Liu; C-X Gong; I Grundke-Iqbal
Journal:  Curr Alzheimer Res       Date:  2010-12       Impact factor: 3.498

Review 2.  Endoplasmic reticulum enrollment in Alzheimer's disease.

Authors:  Ricardo J S Viana; Ana F Nunes; Cecília M P Rodrigues
Journal:  Mol Neurobiol       Date:  2012-07-20       Impact factor: 5.590

3.  Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline.

Authors:  Sarah Gourmaud; Claire Paquet; Julien Dumurgier; Clarisse Pace; Constantin Bouras; Françoise Gray; Jean-Louis Laplanche; Eliane F Meurs; François Mouton-Liger; Jacques Hugon
Journal:  J Psychiatry Neurosci       Date:  2015-05       Impact factor: 6.186

Review 4.  Neuropathological alterations in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

5.  Granulovacuolar degeneration (GVD) bodies of Alzheimer's disease (AD) resemble late-stage autophagic organelles.

Authors:  K E Funk; R E Mrak; J Kuret
Journal:  Neuropathol Appl Neurobiol       Date:  2011-04       Impact factor: 8.090

Review 6.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

7.  Detergent-insoluble EAAC1/EAAT3 aberrantly accumulates in hippocampal neurons of Alzheimer's disease patients.

Authors:  Kevin Duerson; Randall L Woltjer; Paramita Mookherjee; James B Leverenz; Thomas J Montine; Thomas D Bird; David V Pow; Thomas Rauen; David G Cook
Journal:  Brain Pathol       Date:  2008-07-02       Impact factor: 6.508

8.  Progressive supranuclear palsy in a family with TDP-43 pathology.

Authors:  A Kertesz; E Finger; J Murrell; H Chertkow; L C Ang; M Baker; T Ravenscroft; R Rademakers; D G Munoz
Journal:  Neurocase       Date:  2014-01-30       Impact factor: 0.881

9.  Altered subcellular distribution of c-Abl in Alzheimer's disease.

Authors:  Zheng Jing; John Caltagarone; Robert Bowser
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 10.  ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology.

Authors:  Antero Salminen; Anu Kauppinen; Tiina Suuronen; Kai Kaarniranta; Johanna Ojala
Journal:  J Neuroinflammation       Date:  2009-12-26       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.